Mexico
· Delayed Price · Currency is MXN Voyager Therapeutics Company Description
Voyager Therapeutics, Inc., a biotechnology company, focuses on the human genetics for the cure of neurological diseases.
The company’s lead product candidate is VY7523, an anti-tau antibody program for the treatment of alzheimer’s disease (AD).
Its product pipeline includes VY1706, a tau silencing gene therapy in preclinical trial for the treatment of alzheimer’s disease; SOD1 silencing gene therapy program for treating amyotrophic lateral sclerosis in preclinical trial; and vectorized anti-amyloid antibody early research program for the treatment of AD in preclinical trial.
The company is also developing VY-FXN01 for treating friedreich’s ataxia; and GBA1 gene replacement program to treat parkinson’s disease.
In addition, it provides research program for the treatment of Huntington’s disease. The company has collaboration and license agreements with Alexion; AstraZeneca Ireland Limited; Novartis Pharma AG; and Neurocrine Biosciences, Inc. for the treatment of various other diseases of the central nervous system.
Voyager Therapeutics, Inc. was incorporated in 2013 and is headquartered in Lexington, Massachusetts.
| Country | United States |
| Founded | 2013 |
| Industry | Biological Products, Except Diagnostic Substances |
| Employees | 172 |
| CEO | Alfred Sandrock |
Contact Details
Address: 75 Hayden Avenue Lexington, Delaware 02421 United States | |
| Phone | 857 259 5340 |
| Website | voyagertherapeutics.com |
Stock Details
| Ticker Symbol | VYGR |
| Exchange | Mexican Stock Exchange |
| Stock Type | Common Stock |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| SIC Code | 2836 |
Key Executives
| Name | Position |
|---|---|
| Alfred Sandrock | Chief Executive Officer |
| Nathan Jorgensen | Chief Financial Officer |
| Robin Swartz | Chief Operating Officer |